Current prospects for RNA interference-based therapies
By B. Davidson, P. McCray. Nature reviews genetics, 2011
759 citations recorded by the source corpus.
RNA interference (RNAi) is a powerful approach for reducing expression of endogenously expressed proteins. It is widely used for biological applications and is being harnessed to silence mRNAs encoding pathogenic proteins for therapy. Various methods — including delivering RNA oligonucleotides and expressing RNAi triggers from viral vectors — have been developed for successful RNAi in cell culture and in vivo. Recently, RNAi-based gene silencing approaches have been demonstrated in humans, and ongoing clinical trials hold promise for treating fatal disorders or providing alternatives to traditional small molecule therapies. Here we describe the broad range of approaches to achieve targeted gene silencing for therapy, discuss important considerations when developing RNAi triggers for use in humans, and review the current status of clinical trials.
Subfields: Genetics, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/e432012f1808523fd68766c3157197dc962d6f63
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Molecular Biology
Citations in the corpus
- Molecular mechanisms of RNA interference (2013, neutral): “Although the field shows great promise, challenges with delivery as well as harmful off-target effects have prevented any such drug from reaching the market so far (14).”
- RNAi-Based Insecticidal Crops: Potential Effects on Nontarget Species (2013, background): “High levels of exogenous siRNAs can saturate a cell’s RNAi machinery and thereby reduce the efficiency at which a cell regulates endogenous gene expression (Agrawal et al. 2003, Dillin 2003).”